PT - JOURNAL ARTICLE AU - Bar-On, Yinon M. AU - Goldberg, Yair AU - Mandel, Micha AU - Bodenheimer, Omri AU - Freedman, Laurence AU - Kalkstein, Nir AU - Mizrahi, Barak AU - Alroy-Preis, Sharon AU - Ash, Nachman AU - Milo, Ron AU - Huppert, Amit TI - BNT162b2 vaccine booster dose protection: A nationwide study from Israel AID - 10.1101/2021.08.27.21262679 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.27.21262679 4099 - http://medrxiv.org/content/early/2021/08/31/2021.08.27.21262679.short 4100 - http://medrxiv.org/content/early/2021/08/31/2021.08.27.21262679.full AB - Background On July 30, 2021, a third (booster) dose of the Pfizer BNT162b2 vaccine was approved in Israel for individuals 60 years or older who had been fully vaccinated (i.e., received two doses) at least five months previously. Here, we estimate the reduction in relative risk for confirmed infection and severe COVID-19 provided by the booster dose.Methods 1,144,690 individuals aged 60y and older who were eligible for a booster dose were followed between July 30 and August 22, 2021. We defined dynamic cohorts where individuals initially belong to the ‘non-booster’ cohort, leave it when receiving the booster dose and join the ‘booster’ cohort 12 days later. Rates of infection and severe COVID-19 outcomes per person-days at risk were compared between the cohorts using Poisson regression, adjusting for possible confounding factors.Results Twelve days or more after the booster dose we found an 11.4-fold (95% CI: [10.0, 12.9]) decrease in the relative risk of confirmed infection, and a >10-fold decrease in the relative risk of severe illness. Under a conservative sensitivity analysis, we find ≈5-fold protection against confirmed infection.Conclusions In conjunction with safety reports, this study demonstrates the effectiveness of a third vaccine dose in both reducing transmission and severe disease and indicates the great potential of curtailing the Delta variant resurgence by administering booster shots.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Sheba Medical Center. Helsinki approval number: SMC-8228-21.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregated data are given in the supplementary information. Personal data cannot be shared due to privacy.